|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:G04BE03
|
|
gptkbp:availableOn
|
gptkb:tablet
oral suspension
injectable
|
|
gptkbp:brand
|
gptkb:Revatio
gptkb:Viagra
|
|
gptkbp:CASNumber
|
139755-83-2
|
|
gptkbp:chemicalClass
|
gptkb:pyrazolopyrimidinone
|
|
gptkbp:contraindication
|
nitrate medication
severe cardiovascular disorders
|
|
gptkbp:cost
|
varies by country and brand
|
|
gptkbp:developedBy
|
gptkb:United_Kingdom
|
|
gptkbp:discoveredBy
|
gptkb:Pfizer
|
|
gptkbp:discoveredIn
|
1996
|
|
gptkbp:eliminationHalfLife
|
3-5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:genericName
|
yes
|
|
gptkbp:hasMolecularFormula
|
C22H30N6O4S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sildenafil
|
|
gptkbp:interactsWith
|
gptkb:milk
CYP3A4 inhibitors
nitrates
alpha-blockers
|
|
gptkbp:IUPACName
|
gptkb:1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine
|
|
gptkbp:KEGGID
|
D08514
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
PDE5 inhibitor
|
|
gptkbp:MeSH_ID
|
D000068879
|
|
gptkbp:metabolism
|
gptkb:CYP2C9
gptkb:CYP3A4
liver
|
|
gptkbp:notRecommendedFor
|
children under 18 (for ED)
|
|
gptkbp:patentExpired
|
2013
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prescribes
|
adults
|
|
gptkbp:PubChem_CID
|
5212
CHEMBL192
DB00203
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
headache
dyspepsia
flushing
visual disturbances
|
|
gptkbp:UNII
|
3M7OB98Y7H
|
|
gptkbp:usedFor
|
erectile dysfunction
pulmonary arterial hypertension
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
gptkb:Viagra
|
|
gptkbp:bfsLayer
|
5
|